X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with Biocon Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs BIOCON LTD - Comparison Results

BIOCON LTD 
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA BIOCON LTD AJANTA PHARMA/
BIOCON LTD
 
P/E (TTM) x 20.4 92.4 22.0% View Chart
P/BV x 4.8 7.8 61.1% View Chart
Dividend Yield % 0.0 0.1 -  

Financials

 AJANTA PHARMA   BIOCON LTD
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-18
BIOCON LTD
Mar-18
AJANTA PHARMA/
BIOCON LTD
5-Yr Chart
Click to enlarge
High Rs1,8181,188 153.0%   
Low Rs1,106305 362.6%   
Sales per share (Unadj.) Rs239.568.7 348.5%  
Earnings per share (Unadj.) Rs52.87.6 699.1%  
Cash flow per share (Unadj.) Rs59.514.0 426.0%  
Dividends per share (Unadj.) Rs01.00 0.0%  
Dividend yield (eoy) %00.1 0.0%  
Book value per share (Unadj.) Rs230.086.3 266.3%  
Shares outstanding (eoy) m88.77600.00 14.8%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x6.110.9 56.2%   
Avg P/E ratio x27.798.9 28.0%  
P/CF ratio (eoy) x24.653.4 46.0%  
Price / Book Value ratio x6.48.6 73.5%  
Dividend payout %013.2 0.0%   
Avg Mkt Cap Rs m129,782447,900 29.0%   
No. of employees `0006.86.1 110.5%   
Total wages/salary Rs m3,7659,311 40.4%   
Avg. sales/employee Rs Th3,128.46,705.8 46.7%   
Avg. wages/employee Rs Th554.01,514.2 36.6%   
Avg. net profit/employee Rs Th689.7736.9 93.6%   
INCOME DATA
Net Sales Rs m21,25841,234 51.6%  
Other income Rs m2422,062 11.7%   
Total revenues Rs m21,49943,296 49.7%   
Gross profit Rs m6,5848,291 79.4%  
Depreciation Rs m5963,851 15.5%   
Interest Rs m4615 0.7%   
Profit before tax Rs m6,2265,887 105.7%   
Minority Interest Rs m0213 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,5391,569 98.1%   
Profit after tax Rs m4,6864,531 103.4%  
Gross profit margin %31.020.1 154.0%  
Effective tax rate %24.726.7 92.8%   
Net profit margin %22.011.0 200.6%  
BALANCE SHEET DATA
Current assets Rs m12,23641,486 29.5%   
Current liabilities Rs m3,46121,413 16.2%   
Net working cap to sales %41.348.7 84.8%  
Current ratio x3.51.9 182.5%  
Inventory Days Days6064 94.1%  
Debtors Days Days8494 89.7%  
Net fixed assets Rs m11,14050,661 22.0%   
Share capital Rs m1773,000 5.9%   
"Free" reserves Rs m20,23748,808 41.5%   
Net worth Rs m20,41451,808 39.4%   
Long term debt Rs m1017,898 0.1%   
Total assets Rs m24,48699,897 24.5%  
Interest coverage x1,519.410.6 14,371.6%   
Debt to equity ratio x00.3 0.1%  
Sales to assets ratio x0.90.4 210.3%   
Return on assets %19.25.2 371.9%  
Return on equity %23.08.7 262.5%  
Return on capital %30.59.6 316.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m11,66712,058 96.8%   
Fx outflow Rs m1,6167,348 22.0%   
Net fx Rs m10,0524,710 213.4%   
CASH FLOW
From Operations Rs m2,8546,621 43.1%  
From Investments Rs m-2,604-6,840 38.1%  
From Financial Activity Rs m-2-2,397 0.1%  
Net Cashflow Rs m248-2,612 -9.5%  

Share Holding

Indian Promoters % 73.8 40.4 182.7%  
Foreign collaborators % 0.0 20.6 -  
Indian inst/Mut Fund % 1.6 8.4 18.5%  
FIIs % 7.6 10.7 71.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 19.9 85.4%  
Shareholders   20,968 109,995 19.1%  
Pledged promoter(s) holding % 4.4 0.0 10,975.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   ALKEM LABORATORIES  FRESENIUS KABI ONCO.  TTK HEALTHCARE  ASTRAZENECA PHARMA  DISHMAN PHARMA  

Compare AJANTA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

AJANTA PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 11.6% (Quarterly Result Update)

Aug 1, 2018 | Updated on Aug 1, 2018

For the quarter ended June 2018, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 11.6% YoY). Sales on the other hand came in at Rs 5 bn (up 8.0% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

BIOCON LTD Announces Quarterly Results (1QFY19); Net Profit Up 47.2% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, BIOCON LTD has posted a net profit of Rs 1 bn (up 47.2% YoY). Sales on the other hand came in at Rs 11 bn (up 20.4% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Sep 21, 2018 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 5-YR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS